GXP PHARMAID ApS: Financial statements 2013
CVR: 29615861
Source: annual report 2013, Danish Business Authority
01/01/2013 – 31/12/2013
GXP PHARMAID ApS (CVR 29615861) has filed annual accounts for 2013. In 2013, the company reported a gross profit of DKK 2,306,234 and a net result of DKK 450,698. That is an increase of 11.6% compared with the year before. Equity in the 2013 report amounted to DKK 1,133,768. The solvency ratio was 44%.
- Gross Profit
- DKK 2,306,234
- Profit/Loss
- DKK 450,698
- Equity
- DKK 1,133,768
- Total Assets
- DKK 2,579,427
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2013 | - | 2.3 mio. | 451 t. | 1.1 mio. | - |
| 2012 | - | 2.1 mio. | - | - | - |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2013
As of October 30, 2013, Nusret Asanovski has joined the board of directors of GXP PHARMAID ApS.
As of October 30, 2013, Jonas Evjenios Markou has joined the board of directors of GXP PHARMAID ApS.
As of October 30, 2013, Mogens Birch-Larsen has joined the board of directors of GXP PHARMAID ApS.
GXP PHARMAID ApS has published its annual report for 2012.
About GXP PHARMAID ApS
GXP PHARMAID ApS is a Danish company of the type Anpartsselskab based in Brønshøj, founded in 2006. The company is registered under the industry Anden teknisk rådgivning. The company was previously named Q-VIGILANCE ApS. The management consists of Nusret Asanovski. The company is owned by MAC ANDORBY ApS. The company has 1 employee (2026). In 2025, the company reported a gross profit of DKK 1,163,256 and a net result of DKK 122,320 compared with DKK 216,532 the year before. Equity in the 2025 report amounted to DKK 1,218,531.